skip to Main Content
  • This page as PDF
March 17, 2020 9:00 - 9:45 PM ET

No sPCMA, No Worries … We’ve Got Part D Covered


Just because we can’t meet at sPCMA doesn’t mean we can’t discuss what’s next for Medicare Part D.

Our experts engaged in a conversation about the outlook for the Part D program and issues to watch during the 2021 bid/contracting cycle and beyond. Our panelists explored the potential implications of a preferred specialty tier on 2021 and 2022 formularies, the future of Part D benefit redesign, and some key impacts across different types of Part D plans.

Our panelists also answered questions from the audience.


Kelly Brantley , Practice Director, Policy

Kelly Brantley works with biopharmaceutical companies, health insurance plans, and patient organizations to develop customer-specific solutions that predict and respond to the ever-changing health policy landscape.

Miryam Frieder , Practice Director, Policy

Miryam Frieder leads strategic client engagements focused on the drug pricing policy environment, rebate reform models, and Medicare Part D. Miryam advises clients on assessing the impact of the evolving policy landscape to inform business decisions and policy engagement strategies.

Michael Schneider , Principal, Commercialization & Regulatory Strategy
From beginning to end, our team synergy
produces measurable results. Let's work together.
Back To Top